

1-22-2021

Differential expression of $\alpha V\beta 3$ and $\alpha V\beta 6$ integrins in prostate cancer progression

Fabio Quaglia

Thomas Jefferson University

Shiv Ram Krishn

Thomas Jefferson University

Yanqing Wang

Roswell Park Comprehensive Cancer Center

David W Goodrich

Roswell Park Comprehensive Cancer Center

Peter McCue

Thomas Jefferson University

Follow this and additional works at: <https://jdc.jefferson.edu/cbfp>



Part of the [Cancer Biology Commons](#), [Oncology Commons](#), and the [Pathology Commons](#)

See next page for additional authors

[Let us know how access to this document benefits you](#)

Recommended Citation

Quaglia, Fabio; Krishn, Shiv Ram; Wang, Yanqing; Goodrich, David W; McCue, Peter; Kossenkov, Andrew; Mandigo, Amy C; Knudsen, Karen; Weinreb, Paul H; Corey, Eva; Kelly, William Kevin; and Languino, Lucia R, "Differential expression of $\alpha V\beta 3$ and $\alpha V\beta 6$ integrins in prostate cancer progression" (2021). *Department of Cancer Biology Faculty Papers*. Paper 176.

<https://jdc.jefferson.edu/cbfp/176>

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Cancer Biology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors

Fabio Quaglia, Shiv Ram Krishn, Yanqing Wang, David W Goodrich, Peter McCue, Andrew Kossenkov, Amy C Mandigo, Karen Knudsen, Paul H Weinreb, Eva Corey, William Kevin Kelly, and Lucia R Languino

RESEARCH ARTICLE

Differential expression of $\alpha V\beta 3$ and $\alpha V\beta 6$ integrins in prostate cancer progression

Fabio Quaglia^{1,2}, Shiv Ram Krishn^{1,2}, Yanqing Wang³, David W. Goodrich³, Peter McCue⁴, Andrew V. Kossenkov⁵, Amy C. Mandigo², Karen E. Knudsen², Paul H. Weinreb⁶, Eva Corey⁷, William K. Kelly⁸, Lucia R. Languino^{1,2*}

1 Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, PA, United States of America, **2** Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, United States of America, **3** Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States of America, **4** Department of Pathology, Thomas Jefferson University, Philadelphia, PA, United States of America, **5** Center for Systems and Computational Biology, Wistar Institute, Philadelphia, PA, United States of America, **6** Biogen Inc., Cambridge, MA, United States of America, **7** Department of Urology, University of Washington, Seattle, Washington, United States of America, **8** Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, United States of America

* lucia.languino@jefferson.edu



OPEN ACCESS

Citation: Quaglia F, Krishn SR, Wang Y, Goodrich DW, McCue P, Kossenkov AV, et al. (2021) Differential expression of $\alpha V\beta 3$ and $\alpha V\beta 6$ integrins in prostate cancer progression. PLoS ONE 16(1): e0244985. <https://doi.org/10.1371/journal.pone.0244985>

Editor: MOHAMMAD Saleem, University of Minnesota Twin Cities, UNITED STATES

Received: July 3, 2020

Accepted: December 18, 2020

Published: January 22, 2021

Copyright: © 2021 Quaglia et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the manuscript and its [Supporting Information](#) files.

Funding: This study was supported by the National Cancer Institute in the form of grants awarded to LRL (R01-CA224769, P01-CA140043), DWG (R01-CA207757), and KEK (R01-CA176401) and Philadelphia Prostate Cancer Biome Project in the form of funds awarded to WKK (6/01/19- 5/31/23). This project was also funded, in part, under a Commonwealth University Research Enhancement

Abstract

Neuroendocrine prostate cancer (NEPrCa) arises *de novo* or after accumulation of genomic alterations in pre-existing adenocarcinoma tumors in response to androgen deprivation therapies. We have provided evidence that small extracellular vesicles released by PrCa cells and containing the $\alpha V\beta 3$ integrin promote neuroendocrine differentiation of PrCa *in vivo* and *in vitro*. Here, we examined $\alpha V\beta 3$ integrin expression in three murine models carrying a deletion of *PTEN* (SKO), *PTEN* and *RB1* (DKO), or *PTEN*, *RB1* and *TRP53* (TKO) genes in the prostatic epithelium; of these three models, the DKO and TKO tumors develop NEPrCa with a gene signature comparable to those of human NEPrCa. Immunostaining analysis of SKO, DKO and TKO tumors shows that $\alpha V\beta 3$ integrin expression is increased in DKO and TKO primary tumors and metastatic lesions, but absent in SKO primary tumors. On the other hand, SKO tumors show higher levels of a different αV integrin, $\alpha V\beta 6$, as compared to DKO and TKO tumors. These results are confirmed by RNA-sequencing analysis. Moreover, TRAMP mice, which carry NEPrCa and adenocarcinoma of the prostate, also have increased levels of $\alpha V\beta 3$ in their NEPrCa primary tumors. In contrast, the $\alpha V\beta 6$ integrin is only detectable in the adenocarcinoma areas. Finally, analysis of 42 LuCaP patient-derived xenografts and primary adenocarcinoma samples shows a positive correlation between $\alpha V\beta 3$, but not $\alpha V\beta 6$, and the neuronal marker synaptophysin; it also demonstrates that $\alpha V\beta 3$ is absent in prostatic adenocarcinomas. In summary, we demonstrate that $\alpha V\beta 3$ integrin is upregulated in NEPrCa primary and metastatic lesions; in contrast, the $\alpha V\beta 6$ integrin is confined to adenocarcinoma of the prostate. Our findings suggest that the $\alpha V\beta 3$ integrin, but not $\alpha V\beta 6$, may promote a shift in lineage plasticity towards a NE phenotype and might serve as an informative biomarker for the early detection of NE differentiation in prostate cancer.

Program grant with the Pennsylvania Department of Health (H.R.) awarded to LRL (SAP 4100072566). The Department specifically disclaims responsibility for any analyses, interpretations, or conclusions. The establishment and characterization of the LuCaP PDXs was supported by the Pacific Northwest Prostate Cancer SPORE in the form of a grant awarded to EC (P50CA97186), the Department of Defense Prostate Cancer Biorepository Network in the form of a grant awarded to EC (W81XWH-14-2-0183), and National Cancer Institute (NCI) in the form of a grant awarded to EC (P01 CA163227). The research reported in this publication utilized the shared flow cytometry, histopathology, and bioimaging facilities at the Sidney Kimmel Cancer Center (Thomas Jefferson University, Philadelphia, PA) that are supported by the National Cancer Institute of the National Institutes of Health in the form of a grant awarded to KEK (P30CA056036). NIH grants partially support the salaries of FQ, SRK, YW, DWG, AM, KEK, EC, LRL. Biogen Inc. provided support in the form of a salary for PW. The specific roles of this author are articulated in the 'author contributions' section. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors of this study have read the journal's policy and have the following competing interests: PW is an employee and a shareholder of Biogen Inc. Biogen holds patents covering α V β 6 antibodies and their uses for therapeutic purposes. However, this paper does not deal with the use of these antibodies for therapeutic purposes; these antibodies have been used just for immunoblotting in Fig 5. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Introduction

Integrins are transmembrane adhesion receptors that are deregulated during cancer progression [1, 2]. Among others, α V β 6, α V β 3, α 6 β 1, and α 6 β 4 integrins are overexpressed in prostate cancer (PrCa) [3–6]; our group recently demonstrated that small extracellular vesicles released from PrCa cells and containing the α V β 3 integrin induce neuroendocrine differentiation (NED) *in vitro* and *in vivo* [7]. In contrast, the α 5 and α 7 integrin subunits have been reported to be downregulated in PrCa [8].

The α V β 3 integrin, also known as the vitronectin receptor, is composed of two subunits, α V and β 3. It can bind a wide range of extracellular matrix components through its RGD motif (Arg-Gly-Asp) [9] and promotes invasion and adhesion of cancer cells to extracellular matrix proteins [2, 10, 11]. This RGD-integrin binding is also known to facilitate cell adhesion, virus entry, and infection by many human viruses [12], including metapneumovirus [13] and coxsackievirus [14]. According to a recent study, the interaction between the RGD motif in the spike protein of the SARS-Cov-2 virus (responsible for COVID-19) and integrins may promote the entry of the virus into the host cells [15]. The α V β 3 integrin itself is involved in a variety of processes, including angiogenesis and tumor metastasis [16]. While present at very low levels in normal prostate tissues, it is highly expressed in PrCa cells and in metastasis [7, 10, 17]. Given its widespread distribution in PrCa, α V β 3 has been explored as a therapeutic target in some studies [18, 19].

Dysregulated expression of the α V β 6 integrin, another RGD binding integrin, has been associated with poor outcomes in different types of cancer [20]. Previous studies from our group showed that α V β 6 integrin is upregulated in PrCa and PrCa bone metastases [21, 22].

Neuroendocrine PrCa (NEPrCa), a subtype of PrCa that typically develops from subsets of castrate-resistant PrCa (CRPrCa) cells, is highly aggressive and usually metastasizes [23]. NEPrCa tumors may develop *de novo* or through the acquisition of alterations in pre-existing epithelial tumors in response to therapies as outlined in the recent National Cancer Institute workshop "Perspective on Lineage Plasticity and AR-independent PrCa" [24]. *De novo* NEPrCa appears to result from lineage reprogramming of mature differentiated cells that do not express androgen receptor (AR) or prostate-specific antigen (PSA) but instead express neuron-specific proteins, such as aurora kinase A (AURKA), synaptophysin (SYP), and neuron-specific enolase (NSE) [25–27]. These aberrations promote pro-tumorigenic pathways independently from those activated by the AR [28]. Treatment-emergent NEPrCa has similar characteristics but, at variance, it acquires expression of the AR [29]. From a clinical perspective, NEPrCa quickly develops resistance to chemotherapy and is associated with a life expectancy of less than one year [25, 30].

Here we show, for the first time, that α V β 3 integrin expression is increased in NEPrCa, but absent in prostatic adenocarcinomas (ADPrCa). Our immunohistochemical analysis of PrCa samples reveals differential expression of the α V β 3 and α V β 6 integrins. We find that the α V β 3 integrin is highly expressed in metastases from NEPrCa patients while α V β 6 integrin is mostly expressed in ADPrCa lacking neuroendocrine features. We also show that α V β 3 expression is increased in a murine model that lacks the *PTEN*, *RB1*, and *TRP53* genes and develops NEPrCa resembling its human counterpart. Loss of *PTEN* and *RB1*, with intact *TRP53*, also causes increased expression of α V β 3 integrin, although to a lower extent. Moreover, we report increased α V β 3 integrin expression in the tumors of TRAMP (Transgenic Adenocarcinoma of the Mouse Prostate) mice that develop NEPrCa together with castrate-sensitive ADPrCa. We confirmed these results by screening of 42 LuCaP patient-derived xenografts (PDXs) [31, 32]. Our analysis uncovers a positive correlation between α V β 3 integrin and SYP but not between α V β 6 and this NE marker. Our study provides novel insights into the identification of new

pathways that might promote lineage plasticity among PrCa subtypes for which there is no established therapeutic approach. The differential expression of these two lineage-restricted integrins might also serve as a useful biomarker to predict neuroendocrine differentiation and facilitate patient stratification in PrCa.

Materials and methods

Cell lines

PrCa C4-2B and LNCaP cell culture conditions have been previously described [10, 33].

Antibodies

Immunohistochemistry (IHC) analysis used two different rabbit monoclonal antibodies (Abs) against β 3 integrin subunit: one from Cell Signaling (13166S; Figs 1 and 2) and another from AbCam (Ab75872; Fig 4). Moreover, a rabbit polyclonal Ab against SYP (Invitrogen, PA1-1043) and a rabbit polyclonal Ab against chromogranin A (CgA, Invitrogen, 18-0094) were used. For the β 6 integrin subunit, a mouse monoclonal Ab against the β 6 integrin subunit (6.2A1) [34] was used for immunostaining of human samples, and a human/mouse chimeric Ab against the β 6 integrin subunit (ch2A1) [35] was used for SKO, DKO, and TKO murine samples. Immunoblotting analysis used rabbit monoclonal Ab against β 3 integrin subunit (Cell Signaling, 13166S), rabbit polyclonal Abs against TSG101 (Abcam, ab30871), actin (Sigma, A2066), and a mouse monoclonal Ab against the β 6 integrin subunit (6.2A1).

Generation of mice carrying prostate-specific TRP53 and RB1 gene deletions

Mice of genotype PB-Cre4 *PTEN*^{loxP/loxP}, PB-Cre4 *PTEN*^{loxP/loxP}*RB1*^{loxP/loxP}, or PB-Cre4 *PTEN*^{loxP/loxP}*RB1*^{loxP/loxP}*TRP53*^{loxP/loxP} were generated as previously described [36, 37]. Briefly, mice carrying different combinations of the *PTEN*^{loxP}, *RB1*^{loxP}, and *TRP53*^{loxP} alleles were interbred, with the ARR2PB-Cre transgene from the PB-Cre4 line always carried through males. Mice used in this analysis are on a C57BL/6 and 129SVJ mixed genetic backgrounds. Mice were backcrossed to the C57BL/6 strain for at least 5 generations. Genotypes were designated as SKO (single *PTEN* knock-out), DKO (double *PTEN:RB1* knock-out), and TKO (triple *PTEN:RB1:TRP53* knock-out). Non-recombinant littermates were used as a control. The mice were euthanized using CO₂ and cervical dislocation when the tumor length was approximately 2 cm. All of these mice were maintained following guidelines of the Institutional Animal Care and Use Committee (IACUC), and were bred and kept at Roswell Park Comprehensive Cancer Center (Buffalo, NY, USA).

TRAMP (Transgenic Adenocarcinoma of the Mouse Prostate) mice

Male TRAMP mice were generated as described previously [38]. Twenty-four male TRAMP mice were used. No female mice were analyzed in this study. The mice were euthanized using CO₂ and cervical dislocation when the tumor volume was approximately 10,000 mm³. Care of animals was in compliance with standards established by the Office of Laboratory Animal Welfare, NIH, Department of Health and Human Services. All mice were maintained following recommendations of the IACUC. Experimental protocols were approved by IACUC.

PDX establishment

The acquisition of PrCa patient tissues and their use to establish PDX models have been described [32]. The vast majority of implanted tissues was from metastatic foci obtained at




Fig 1. α V β 3 integrin is selectively upregulated in the primary tumors of mice carrying neuroendocrine prostate cancer. Immunostaining of the α V β 3 integrin (top panels), α V β 6 integrin (middle panels), and SYP (bottom panels) in prostate tumors from murine models with genetic knockdown of PTEN (SKO; n = 5), PTEN and RB1 (DKO; n = 5), and PTEN, RB1, and TRP53 (TKO; n = 5) in the prostatic epithelium. The bar at the bottom right corner of each panel represents 50 μ m. First column: SKO; second column: DKO; third column: TKO.

<https://doi.org/10.1371/journal.pone.0244985.g001>

tissue acquisition necropsy in a manner which limited warm ischemic time as much as possible (aiming for 4–8 hours after death). A few samples of primary PrCa were obtained from surgical procedures. Harvested tumor tissues were evaluated by pathologists, and viable tumor tissue was macro-dissected to minimize content of stroma, fat, and necrotic tissue. Tumor fragments were implanted subcutaneously in 6- to 8-week-old intact male athymic Nu/Nu (NU-*Foxn1nu*) or CB-17 severe combined immunodeficient (SCID, CB17/*Icr-Prkdcscid/IcrCrl*) mice (Charles River Laboratory). Tumor samples were harvested from later passages (>3) and frozen or embedded in paraffin for characterization. LuCaP PDXs are maintained by constant passaging in SCID mice. The levels of SYP in the LuCaP PDX were assessed by IHC analysis.




Fig 2. $\alpha V\beta 3$ integrin is selectively upregulated in lung metastases of mice carrying neuroendocrine prostate cancer. Immunostaining of the $\alpha V\beta 3$ integrin (top panels), $\alpha V\beta 6$ integrin (middle panels), and SYP (bottom panels) in the lung metastases from murine models with genetic knockdown of PTEN and RB1 (DKO; n = 5) and PTEN, RB1, and TRP53 (TKO; n = 5) in the prostatic epithelium. The bar at the bottom right corner of each panel represents 20 μm . First column: DKO; second column: TKO.

<https://doi.org/10.1371/journal.pone.0244985.g002>

Immunohistochemistry (IHC)

IHC was performed on tissue sections from SKO (n = 5), DKO (n = 5), and TKO (n = 5) prostate tumors and lung metastases, from TRAMP murine primary tumors, and on LuCaP PDX TMA containing 42 PDX models. Of the 24 TRAMP mice analyzed, 13 exhibited a NE phenotype, 11 presented adenocarcinoma lesions, and 5 displayed both characteristics. The tissue sections were baked at 60°C for 1 hour, followed by deparaffinization with xylene (3 min \times 2), and rehydration through a graded ethanol series (100%, 90%, 70%, 50%, 30% for 3 min each) followed by deionized water (3 min \times 2). The sections were incubated with 3% H₂O₂ solution for quenching endogenous peroxidase activity, followed by heat-induced antigen retrieval for the $\beta 3$ integrin subunit, SYP or chromogranin (CgA) that was performed in citrate buffer (10 mM sodium citrate, 0.05% Tween 20, pH 6.0) at 95°C for 15 min. For $\beta 6$ integrin subunit immunostaining, antigen retrieval was performed using pepsin (0.5% in 5 mM HCl) digestion for 15 min at 37°C. Sections were washed once with deionized water for 5 min, followed by a phosphate buffer saline (PBS) wash for 5 min, and blocked with 5% goat serum in PBST (PBS, 0.1% Tween20) for 2 hours. The tissue sections were incubated overnight at 4°C with Abs against $\beta 3$ integrin subunit (1:25), $\beta 6$ integrin subunit (2 $\mu\text{g}/\text{ml}$), CgA (1 $\mu\text{g}/\text{ml}$), SYP (5 $\mu\text{g}/\text{ml}$), or the respective IgG isotype, which was used as negative control. The following day, the tissue sections were washed with PBST (5 min \times 2), followed by PBS (5 min), and incubated with secondary Abs (biotinylated goat anti-rabbit IgG in PBST for $\beta 3$ integrin, SYP, or CgA, and biotinylated goat anti-human or horse anti-mouse IgG for $\beta 6$ integrin, 10 $\mu\text{g}/\text{ml}$ in PBST) for 30 min at room temperature. The unbound secondary Ab was washed with PBST (5 min \times 2), followed by PBS (5 min). The tissue sections were incubated with streptavidin horseradish peroxidase (SAP, 5 $\mu\text{g}/\text{ml}$ in PBS) for 30 min at room temperature and the unbound SAP was washed with PBST (5 min \times 2), followed by PBS (5 min). The chromogenic reaction product was developed by adding substrate chromogen 3,3'-diaminobenzidine solution (DAB substrate kit). The DAB reaction was stopped by rinsing the tissue sections in deionized water. The sections were counterstained with Harris hematoxylin, dehydrated in a graded ethanol series (30%, 50%, 70%, 90%, 100% for 5 min each) followed by xylene (5 min \times 2), dried, and finally mounted with Permount (Vector Laboratories).

LuCaP TMA immunohistochemical assessment and statistical analysis

LuCaP PDX TMA immunostaining was scored by multiplying each staining intensity level ("0" for no stain, "1" for faint stain, and "2" for definitive stain) by the percentage of cells at each staining level. The multiplicands provided a final score for each sample (score range was 0 to 200). The score for each LuCaP core was the average of the scores of each triplicate. Relative detection levels of SYP were provided by Dr. Corey and defined as 0 (-), 1 (+), 2 (++), and 3 (+++). The normalization was performed by assigning to the higher score for each immunostaining ($\alpha V\beta 3$, $\alpha V\beta 6$, and SYP) a value of 100. Correlation analysis between the integrin scores and the expression levels of SYP and its significance was performed using Spearman correlation (Matlab v.R2016a).

RNA-sequencing (RNA-seq)

RNA-seq was performed as previously reported in [39] and publicly available on GEO Expression Omnibus (accession number: GSE90891). Briefly, RNA-seq was performed on SKO

(n = 4), DKO (n = 5), and TKO (n = 4) prostate tumors and on normal prostate (n = 4) by the Roswell Park Cancer Institute Genomics shared resource. Sequencing libraries were prepared with the TruSeq Stranded Total RNA kit (Illumina Inc) from 1 μ g total RNA following manufacturer's instructions. After ribosomal RNA depletion, RNA was purified, fragmented, and primed for cDNA synthesis. Fragmented RNA was reverse transcribed into first-strand cDNA using random primers. AMPure XP beads were used to separate the cDNA from the second-strand reaction mix resulting in blunt-ended cDNA. A single 'A' nucleotide was then added to the 3' ends of the blunt fragments. Multiple indexing adapters, containing a single 'T' nucleotide on the 3' end of the adapter, were ligated to the ends of the cDNA to prepare them for hybridization onto a flow cell. Libraries were purified and validated for the appropriate size on a 2100 Bioanalyzer High Sensitivity DNA chip (Agilent Technologies, Inc.). The DNA library was quantitated using KAPA Biosystems qPCR kit and normalized to 2 nM prior to pooling. Libraries were pooled in an equimolar fashion and diluted to 10 pM. Library pools were clustered and run on a HiSeq2500 rapid mode sequencer according to the manufacturer's recommended protocol (Illumina Inc.).

Raw sequencing reads passing the Illumina RTA quality filter were pre-processed using FASTQC for sequencing base quality control. Reads were mapped to the mouse reference genome (mm9) and RefSeq annotation database using Tophat. A second round of quality control using RSeQC was applied to mapped bam files to identify potential RNA-seq library preparation problems. The number of reads aligning to each gene was calculated using HTSeq, and for each gene, the corresponding RPKM value was calculated.

For differential gene expression analysis, RNA-seq counts were processed to remove genes lacking expression in more than 80% of samples. Scale normalization was done using the Limma package in R. After Voom transformation, data from primary SKO, DKO, and TKO tumors were compared to generate differentially expressed gene lists with $P < 0.05$ and $\log_{2}FC > 1.5$.

Human subject inclusion criteria

Three metastatic ADPrCa tissue samples (Gleason Score GS 9 [n = 1] and GS 10 [n = 2]) were obtained from the Department of Pathology at Thomas Jefferson University (Philadelphia, PA). Additionally, four human malignant ADPrCa tissue samples (GS 7 [n = 3] and GS 10 [n = 1]) were obtained from the Cooperative Human Tissue Network (CHTN) Western Division at Vanderbilt University Medical Center, TN, or Mid-Atlantic Division at University of Virginia, VA. The CHTN is funded by the National Cancer Institute and other investigators may have received specimens from the same subjects. All specimens were de-identified and discarded in accordance with IRB-approved protocols.

siRNA transfection and immunoblotting analysis

Downregulation of AR was accomplished using siRNA SMARTPool (Dharmacon, L-003400-00-0005) and non-targeting siRNA as a control (Dharmacon, D-001810-10-05). Transfection of siRNA and immunoblotting analysis were performed as previously described [21].

Results

The $\alpha V\beta 3$ integrin is selectively upregulated in NEPrCa murine models

In a recent study, we have shown that the $\alpha V\beta 3$ integrin is found in small extracellular vesicles released by cancer cells and that small extracellular vesicles containing $\alpha V\beta 3$ have a unique ability to promote NED of PrCa *in vivo* [7]. Based on these findings, we hypothesized that

elevated expression levels of α V β 3 might correlate with NED in PrCa. We tested this hypothesis by analyzing the levels of α V β 3 and α V β 6 integrins in primary tumors, as well as lung metastatic lesions, from NEPrCa mice carrying *PTEN*, *RB1*, and *TRP53* triple conditional knock-outs in the prostatic epithelium (PBCre4 *PTEN*^{loxP/loxP} *RB1*^{loxP/loxP} *TRP53*^{loxP/loxP}, TKO). This model has been reported to develop NEPrCa similar to its human counterpart [39]. We compared the TKO model to a double knock-out model lacking *PTEN* and *RB1* in the prostate (PBCre4 *PTEN*^{loxP/loxP} *RB1*^{loxP/loxP}, DKO). In addition, we analyzed a *PTEN* single conditional knock-out mouse model (PBCre4 *PTEN*^{loxP/loxP}, SKO) whose gene expression signature has been shown to be comparable to human ADPrCa [39]. The immunostaining analysis reveals high levels of the α V β 3 integrin (Figs 1 and 2, top panels) which correlate with SYP expression (Figs 1 and 2, bottom panels) in the prostate tumors (Fig 1) and lung metastatic lesions (Fig 2) of DKO and TKO mice (n = 5 for each group). The results are consistent in all samples except for one of the DKO samples which does not exhibit detectable α V β 3 integrin expression. In the tumors from the SKO mice, the α V β 3 integrin is not detectable (Fig 1, top panels), whereas the α V β 6 integrin is highly expressed in SKO prostate tumor samples (Fig 1, middle panels), and is low with some patchy positivity in the DKO and TKO primary tumors (Fig 1, middle panels). Consistent with these results, lung metastatic lesions from DKO and TKO mice show some patchy positivity for the α V β 6 integrin (Fig 2, middle panels) but at a considerably lower level than for α V β 3. We did not observe any metastases in SKO mice.

Consistent with the immunostaining results, RNA sequencing analysis of the publicly available datasets on Geo Expression Omnibus (GSE90891, [39]) reveals higher levels of the β 3 integrin subunit (*ITGB3*) expression in DKO and TKO tumors compared to SKO samples. Moreover, *ITGB3* mRNA is upregulated in SKO compared to normal prostate (wild type, WT; Table 1), although our immunostaining analysis does not detect the α V β 3 integrin in the SKO samples analyzed (Fig 1). These results indicate that, although the *ITGB3* mRNA is present in SKO tumors, the mRNA is likely to be unstable. In addition, the levels of the α V integrin subunit (*ITGAV*) and β 6 integrin subunit (*ITGB6*) are lower in DKO and TKO tumors compared to SKO, although noticeably higher in all three knock-out genotypes compared to normal prostate (WT) samples (Table 1).

NEPrCa expresses elevated levels of PARP1 which is a nuclear enzyme involved in DNA repair, DNA replication, inflammation, and chromosome organization [40, 41]. Consistent with these previous publications, *PARP1* expression is upregulated in DKO and TKO tumors (Table 1). Although *PARP1* mRNA is also upregulated in SKO samples compared to the WT control, the levels of *PARP1* mRNA are not as elevated as in DKO and TKO tumors (Table 1). In addition, another gene involved in NED (BRN4 [*POU3F4*]) [42] is upregulated in DKO and TKO samples but not in SKO (Table 1). These results demonstrate that high expression of *ITGB3* and of genes implicated in NED co-occur in DKO and TKO tumors.

Table 1. RNA sequencing analysis shows increased expression of *ITGB3* mRNA in DKO and TKO tumors.

	WT (n = 4)	SKO (n = 4)	DKO (n = 5)	TKO (n = 4)
<i>ITGB3</i>	23.8	1145.5	3536.4	3018
<i>ITGAV</i>	764.3	22121.3	3262.6	4857.3
<i>ITGB6</i>	22.8	3652.5	2113.8	1033
<i>PARP1</i>	580.8	4434.3	15946.2	10862.5
<i>POU3F4</i>	0	0	86.6	75.5

Normalized read counts for the β 3 integrin subunit (*ITGB3*), α V integrin subunit (*ITGAV*), β 6 integrin subunit (*ITGB6*), *PARP1*, and *BRN4* (*POU3F4*) RNA levels in normal prostate (WT), as well as in SKO, DKO, and TKO prostate tumor samples.

<https://doi.org/10.1371/journal.pone.0244985.t001>

We also performed immunohistochemical analysis of tumor samples from TRAMP mice to assess the levels of α V β 3 and α V β 6 integrin expression in their tumors. This mouse model, which is known to have RB and p53 inactivated, develops NEPrCa together with ADPrCa [43, 44]. Our immunostaining shows that the NE marker chromogranin A (CgA) co-occurs with the α V β 3 integrin in 10 of the 13 TRAMP NE tumor samples analyzed (Fig 3). The α V β 6 integrin, however, is not detected in the NE tumors from the TRAMP model (Fig 3). In contrast, the α V β 6 integrin is detected exclusively in the ADPrCa, NE-negative areas of the TRAMP tumor samples (Fig 3). Our results, from the DKO and TKO NE mouse genetic models as well as the TRAMP mice, taken together, clearly demonstrate a consistent correlation between the high expression of α V β 3 integrin and NEPrCa occurrence. Conversely, ADPrCa tumors are consistently associated with expression of the alternative α V β 6 integrin subtype.

Expression of α V β 3 integrin and synaptophysin correlates in patient-derived xenografts

To confirm these results in human specimens, we conducted an immunohistochemical analysis of 42 LuCaP PDXs [31, 32]. These PDX models were generated by implanting primary PrCa or metastatic lesion tumor fragments from PrCa patients into immunocompromised mice [32], and the resulting PDX models were subsequently characterized for their expression of NE markers [31]. We assessed the presence of α V β 3 or α V β 6 integrin using immunohistochemical analysis and scored the immunostaining intensity of each LuCaP core in the tumor micro-array (TMA) using the scoring system described in the Materials and Methods section. We observe a positive correlation between the α V β 3 integrin and the NE marker SYP (Fig 4A and 4B, $r = 0.42$; $P = 0.0046$). In contrast, the α V β 6 integrin shows no correlation with SYP (Fig 4A and 4B, $r = 0.22$; $P = 0.1622$), confirming the results described above obtained for mouse tumor samples.

We further validated the results obtained using the LuCaP PDX TMA by screening PrCa samples from the Department of Pathology at Thomas Jefferson University and the Cooperative Human Tissue Network. Of the 7 ADPrCa primary tumors none expresses α V β 3 (Fig 4C). On the other hand, as previously reported [21], most of the ADPrCa express α V β 6 which was used as positive control. These findings suggest a differential expression of these two α V integrins during PrCa progression, whereby the α V β 3 integrin is specifically expressed in NEPrCa samples, and in contrast, the α V β 6 integrin is specifically expressed in ADPrCa samples lacking NE characteristics.

Loss of androgen receptor signaling does not result in upregulation of α V β 3 or α V β 6 integrin expression in PrCa cell lines



NEPrCa is characterized by the activation of pro-tumorigenic pathways independently from the AR signaling [28]. We hypothesized that loss of AR signaling might induce upregulation of the α V β 3 integrin in LNCaP and C4-2B, two AR positive PrCa cell lines. To test our hypothesis, we downregulated AR expression in LNCaP and C4-2B cells using siRNA. Our results show that downregulation of AR in C4-2B or LNCaP cells does not upregulate α V β 3 (Fig 5A) or α V β 6 integrin (Fig 5B) expression. Thus, it is possible that other factors in the tumor micro-environment contribute to the regulation of α V β 3 integrin and α V β 6 integrin expression after AR signaling loss.

Discussion



Our results demonstrate that increased expression of the α V β 3 integrin correlates with the occurrence of NE markers in human patients' samples and murine models. In contrast, the

TRAMP: Adenocarcinoma Neuroendocrine



$\alpha V\beta 3$
Integrin





$\alpha V\beta 6$
Integrin



CgA



IgG



Primary Tumors n = 24

Fig 3. Selective upregulation of $\alpha V\beta 3$ integrin in the TRAMP (Transgenic Adenocarcinoma of the Mouse Prostate) mice. IHC staining of $\alpha V\beta 3$ (first row), $\alpha V\beta 6$ (second row), and chromogranin A (CgA, third row) of prostate tumors from TRAMP mice (n = 24). Of the 24 samples analyzed, 13 show only a NE phenotype, 11 show only ADPrCa lesions, and 5 show both characteristics. IgG was used as negative control (last row). The bar at the bottom right corner of each panel represents 50 μ m. Left column, ADPrCa; right column, NEPrCa.

<https://doi.org/10.1371/journal.pone.0244985.g003>




Fig 4. Increased expression of the α V β 3 integrin, but not α V β 6, correlates with the neuroendocrine marker SYP in LuCaP PDXs and human prostate tumor samples. Immunohistochemical analysis of 42 LuCaP PDX models. (A) representative IHC staining for α V β 3 (left) or α V β 6 (right) integrin of SYP positive (top row) or SYP-negative (bottom row) LuCaP PDX models is shown. The bar at the bottom right corner of each panel represents 20 μ m. (B) Heat map of the signature score for SYP, α V β 3 or α V β 6 integrin of each LuCaP is shown. Raw data are reported in the S1 Table. (C) Immunostaining analysis of α V β 3 and α V β 6 integrins and SYP primary tumors from ADPrCa patients. The bar at the bottom right corner of each panel represents 20 μ m.

<https://doi.org/10.1371/journal.pone.0244985.g004>




Fig 5. Downregulation of androgen receptor does not increase $\alpha V\beta 3$ or $\alpha V\beta 6$ integrin expression. Immunoblotting analysis of C4-2B and LNCaP cell lysates after AR downregulation by siRNA to AR. (A) Expression levels of $\alpha V\beta 3$ integrin in C4-2B and LNCaP cells after AR downregulation. Immunoblotting was performed under reducing conditions. (B) Expression levels of $\alpha V\beta 6$ integrin in C4-2B and LNCaP cells after AR downregulation. Immunoblotting was performed under non-reducing conditions. Actin or TSG101 serves as loading controls. NS, non-silencing.

<https://doi.org/10.1371/journal.pone.0244985.g005>

$\alpha V\beta 6$ integrin is expressed in human and murine ADPrCa, suggesting that the $\alpha V\beta 3$, but not $\alpha V\beta 6$, integrin might serve as a suitable biomarker to characterize NED in the context of PrCa.

Here, we show that these two integrins are differentially expressed in ADPrCa and NE cancers. Specifically, expression of the $\alpha V\beta 3$ integrin in primary prostate tumors and metastatic lesions of mice carrying deletions of the *PTEN* (SKO), *RB1* and *PTEN* (DKO) or *RB1*, *PTEN*, and *TP53* (TKO) inversely correlates with $\alpha V\beta 6$. Expression of the $\alpha V\beta 3$ integrin in primary prostate tumors of mice carrying deletions of the *PTEN* (SKO) is undetectable, while it is significantly increased in DKO or TKO tumors and metastatic lesions. This indicates that *RB1* loss, and consequent activation of transcription factors of the E2F family [45–47], is sufficient to induce $\alpha V\beta 3$ expression in these models. This integrin expression persists in TKO tumors which, in contrast to DKO tumors exhibiting both SYP and AR expression, develop homogeneous AR-negative NEPrCa, similar to its human counterpart [39]. It remains to be investigated whether downregulation of $\alpha V\beta 6$ and gain of the $\alpha V\beta 3$ integrin occur in CRPrCa since *RB1* is known to influence integrin expression [48, 49], and its loss occurs frequently in human CRPrCa [50, 51].

A factor that may influence the processing of the $\alpha V\beta 3$ integrin, is the expression of the αV subunit which is required for the heterodimeric complex. The RNA analysis summarized here (Table 1) indicates that the levels of the αV integrin subunit (*ITGAV*) become limiting and that $\beta 3$ acts in a dominant fashion over the $\beta 6$ integrin subunit.

We also detect high $\alpha V\beta 3$ integrin expression in the NE areas of primary tumors from TRAMP mice that develop NEPrCa together with ADPrCa. In contrast, we detect the related $\alpha V\beta 6$ integrin in the ADPrCa areas of the TRAMP tumors. Our findings underline the specificity of the $\alpha V\beta 3$ integrin in NEPrCa, nominating this integrin as a potential biomarker for patient stratification in PrCa treatment. Our future studies will benefit from the use of mice carrying deletion of the $\alpha V\beta 3$ integrin crossed with the DKO, TKO, or TRAMP mice, in order to shed new light on the mechanism of action of the $\alpha V\beta 3$ integrin in NEPrCa development and/or metastatic progression.

Multiple strategies have been developed to target the $\alpha V\beta 3$ integrin due to its role in tumor angiogenesis and tumor growth [16]. For example, LM609, an inhibitory antibody against the $\alpha V\beta 3$ integrin, reduced angiogenesis and tumor growth in a SCID mouse/human chimeric model for breast cancer [52]. Its humanized counterpart JC-7U IgG1 has been reported to inhibit tumor growth in a Kaposi sarcoma mouse model and was also able to inhibit, in part, the binding of human immunodeficiency virus (HIV-1) Tat protein to $\alpha V\beta 3$ integrin, which is necessary to stimulate Kaposi sarcoma growth [16, 53]. Previous studies also reported the ability of the $\alpha V\beta 3$ integrin to support metastasis in PrCa [54] as well as other cancers [55–58]. Likewise, the expression of the $\alpha V\beta 3$ integrin conceivably facilitates the metastatic behavior of NEPrCa. In support of this idea, our SKO mouse model (PB-Cre4 *PTEN*^{loxP/loxP}) does not metastasize and expresses low levels of $\alpha V\beta 3$ integrin, whereas DKO and TKO, the two NE models that acquire $\alpha V\beta 3$ integrin expression as a consequence of additional *RB1* knock-out, develop metastases in the lungs [39]. We can speculate that upon *RB1* loss, downregulation of $\alpha V\beta 6$ and gain of the $\alpha V\beta 3$ integrin are required in the primary tumors in the early stages of NED to confer upon NEPrCa the ability to metastasize in different sites (Fig 6). Upon metastasizing, the $\alpha V\beta 3$ integrin expression is sustained as shown here and as previously described [7] in NEPrCa bone metastasis, indicating additional pro-survival functions provided by this integrin.

Whether one or more of the many pathways activated by the $\alpha V\beta 3$ integrin is involved in NED remains to be established. For example, the expression of the $\alpha V\beta 3$ integrin reportedly stimulates cell migration by activation of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway [59]. Other studies have demonstrated that AKT1 is involved in stabilizing N-MYC [60, 61], one of the main promoters of NED in PrCa [62]. Since pAKT is not detectable in TKO prostate tissue [39], we speculate that pAKT activated by $\alpha V\beta 3$ primes the cells to stabilize N-MYC but is not required for long-lasting NED. The RNA-seq analysis presented here highlights potential downstream effectors of $\alpha V\beta 3$. For example, $\alpha V\beta 3$ integrin might be able to induce NED in PrCa by upregulating *Trop2* expression, which is known to induce NEPrCa by upregulation of *PARP1* [40]. Underlining the importance of targeting this pathway to prevent or delay the most aggressive forms of PrCa, the U.S. Food and Drug Administration has recently approved olaparib, a *PARP1* inhibitor [63], for the treatment of metastatic CRPrCa. However, there are as yet no reports on the safety or efficacy of olaparib for the treatment of NEPrCa.

Our previous study demonstrates that the dysregulated expression of the $\alpha V\beta 3$ integrin in small extracellular vesicles released by PrCa cells promotes a shift in lineage plasticity towards a NE lineage [7]. Moreover, although our group has reported that the $\alpha V\beta 6$ integrin, in small extracellular vesicles released by cancer cells, induces M2 polarization in recipient monocytes [64] and stimulates angiogenesis in endothelial cells during cancer progression [65], is absent in NEPrCa. Here we show that the $\alpha V\beta 3$ integrin is upregulated in tumor samples from patients affected by NEPrCa and in corresponding NE murine models. Moreover, our findings demonstrate that conversely, the expression of the $\alpha V\beta 6$ integrin is upregulated in ADPrCa samples from humans and mice. It is therefore reasonable to speculate that monitoring the expression of these two integrins during PrCa progression will help to predict the potential for NED in PrCa patients. Moreover, based on our emerging findings that NE metastatic lesions express relatively




Fig 6. Schematic representation of the findings described in this study. SKO (PB-Cre4 $PTEN^{loxP/loxP}$) cancer cells do not metastasize and express low levels of α V β 3 integrin and high levels of α V β 6 integrin. On the other hand, DKO and TKO tumors (PB-Cre4 $PTEN^{loxP/loxP}$ $RB1^{loxP/loxP}$ and PB-Cre4 $PTEN^{loxP/loxP}$ $RB1^{loxP/loxP}$ $TRP53^{loxP/loxP}$ respectively) express high levels of α V β 3 integrin and low levels of α V β 6 integrin. These α V β 3 positive tumors acquire metastatic behavior and expression of NE markers.

<https://doi.org/10.1371/journal.pone.0244985.g006>

high levels of the α V β 3 integrin, targeted therapies directed against this integrin might prove to be effective in preventing or delaying plasticity and metastasis in NEPrCa [56].

Supporting information

S1 Table. Raw data of the signature score used to generate the heatmap in Fig 4.
(TIF)

S1 Raw images.
(PDF)

Acknowledgments

The authors would like to thank Dr. Misha Beltran and Dr. Martin Backht for useful discussions about NEPrCa and sharing with us their expertise in NED; Dr. Dario C. Altieri and Dr.

Shelia Violette, for the insightful discussion; Dr. Huimin Lu for immunostaining assistance; Dr. Mark Fortini and Jennifer Wilson for editing comments; and Veronica Robles for administrative assistance with the preparation of the manuscript. We would also like to thank Wei Jiang and Zhijiu Zhong, Translational Research/Pathology Facility at Thomas Jefferson University for technical support with tissue processing. Moreover, we would like to thank Dr. Colm M. Morrissey for useful discussion.

Author Contributions

Conceptualization: Fabio Quaglia, Lucia R. Languino.

Data curation: Fabio Quaglia, Yanqing Wang, Amy C. Mandigo.

Formal analysis: Fabio Quaglia, David W. Goodrich, Peter McCue, Andrew V. Kossenkov, Amy C. Mandigo, Karen E. Knudsen, Lucia R. Languino.

Funding acquisition: David W. Goodrich, Karen E. Knudsen, Lucia R. Languino.

Investigation: Fabio Quaglia, Shiv Ram Krishn, Yanqing Wang.

Methodology: Fabio Quaglia.

Resources: Yanqing Wang, David W. Goodrich, Paul H. Weinreb, Eva Corey, Lucia R. Languino.

Supervision: William K. Kelly.

Validation: Peter McCue, Andrew V. Kossenkov.

Writing – original draft: Fabio Quaglia, Lucia R. Languino.

Writing – review & editing: David W. Goodrich, Andrew V. Kossenkov, Amy C. Mandigo, Karen E. Knudsen.

References

1. Hamidi H, Ivaska J. Every step of the way: integrins in cancer progression and metastasis. *Nat Rev Cancer*. 2018; 18(9):533–48. <https://doi.org/10.1038/s41568-018-0038-z> PMID: 30002479; PubMed Central PMCID: 6629548.
2. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. *Nat Rev Cancer*. 2010; 10(1):9–22. Epub 2009/12/24. nrc2748 [pii] <https://doi.org/10.1038/nrc2748> PMID: 20029421.
3. Goel HL, Li J, Kogan S, Languino LR. Integrins in prostate cancer progression. *Endocr Relat Cancer*. 2008; 15(3):657–64. Epub 2008/06/06. ERC-08-0019 [pii] <https://doi.org/10.1677/ERC-08-0019> PMID: 18524948; PubMed Central PMCID: 2668544.
4. Fornaro M, Manes T, Languino LR. Integrins and prostate cancer metastases. *Cancer Metastasis Rev*. 2001; 20(3–4):321–31. <https://doi.org/10.1023/a:1015547830323> PMID: 12085969.
5. Lu H, Wang T, Li J, Fedele C, Liu Q, Zhang J, et al. α V β 6 Integrin Promotes Castrate-Resistant Prostate Cancer Through JNK1-Mediated Activation of Androgen Receptor. *Cancer Res*. 2016; 1(76):5163–74. Epub 2016/07/28. <https://doi.org/10.1158/0008-5472.CAN-16-0543> PMID: 27450452; PubMed Central PMCID: PMC5012867
6. Cress AE, Rabinovitz I, Zhu W, Nagle RB. The α 6 β 1 and α 6 β 4 integrins in human prostate cancer progression. *Cancer Metastasis Rev*. 1995; 14(3):219–28. <https://doi.org/10.1007/BF00690293> PMID: 8548870.
7. Quaglia F, Krishn SR, Daaboul GG, Sarker S, Pippa R, Domingo-Domenech J, et al. Small extracellular vesicles modulated by α V β 3 integrin induce neuroendocrine differentiation in recipient cancer cells. *J Extracell Vesicles*. 2020; 9(1):1761072. Epub 2020/09/15. <https://doi.org/10.1080/20013078.2020.1761072> PMID: 32922691; PubMed Central PMCID: PMC7448905.
8. Drivalos A, Chrisofos M, Efstathiou E, Kapranou A, Kollaitis G, Koutlis G, et al. Expression of alpha5-integrin, alpha7-integrin, Epsilon-cadherin, and N-cadherin in localized prostate cancer. *Urol Oncol*.

- 2016; 34(4):165.e11–8. Epub 2015/12/15. <https://doi.org/10.1016/j.urolonc.2015.10.016> Epub 2015 Dec 2. PMID: 26652134.
9. Nieberler M, Reuning U, Reichart F, Notni J, Wester HJ, Schwaiger M, et al. Exploring the Role of RGD-Recognizing Integrins in Cancer. *Cancers (Basel)*. 2017; 9(9). <https://doi.org/10.3390/cancers9090116> PMID: 28869579; PubMed Central PMCID: PMC5615331.
 10. Zheng DQ, Woodard AS, Fornaro M, Tallini G, Languino LR. Prostatic carcinoma cell migration via α (v) β 3 integrin is modulated by a focal adhesion kinase pathway. *Cancer Res*. 1999; 59(7):1655–64. Epub 1999/04/10. PMID: 10197643.
 11. Stucci S, Tucci M, Passarelli A, Silvestris F. α v β 3 integrin: Pathogenetic role in osteotropic tumors. *Crit Rev Oncol Hematol*. 2015; 96(1):183–93. Epub 2015/07/02. <https://doi.org/10.1016/j.critrevonc.2015.05.018> Epub 2015 Jun 23. PMID: 26126493.
 12. Hussein HA, Walker LR, Abdel-Raouf UM, Desouky SA, Montasser AK, Akula SM. Beyond RGD: virus interactions with integrins. *Arch Virol*. 2015; 160(11):2669–81. Epub 2015/09/01. <https://doi.org/10.1007/s00705-015-2579-8> PMID: 26321473; PubMed Central PMCID: PMC7086847.
 13. Wei Y, Zhang Y, Cai H, Mirza AM, Iorio RM, Peebles ME, et al. Roles of the putative integrin-binding motif of the human metapneumovirus fusion (f) protein in cell-cell fusion, viral infectivity, and pathogenesis. *J Virol*. 2014; 88(8):4338–52. Epub 2014/01/31. <https://doi.org/10.1128/JVI.03491-13> PMID: 24478423; PubMed Central PMCID: PMC3993731.
 14. Williams Ç H, Kajander T, Hyypiä T, Jackson T, Sheppard D, Stanway G. Integrin α v β 6 Is an RGD-Dependent Receptor for Coxsackievirus A9. *J Virol*. 2004; 78(13):6967–73. <https://doi.org/10.1128/JVI.78.13.6967-6973.2004> PMID: 15194773; PubMed Central PMCID: PMC421648.
 15. Sigrist CJ, Bridge A, Le Mercier P. A potential role for integrins in host cell entry by SARS-CoV-2. *Antiviral Res*. 2020; 177:104759. <https://doi.org/10.1016/j.antiviral.2020.104759> PMID: 32130973; PubMed Central PMCID: PMC7114098.
 16. Liu Z, Wang F, Chen X. Integrin α v β 3-Targeted Cancer Therapy. *Drug Dev Res*. 2008; 69(6):329–39. <https://doi.org/10.1002/ddr.20265> PMID: 20628538; PubMed Central PMCID: PMC2901818.
 17. Cooper CR, Chay CH, Pienta KJ. The role of α (v) β 3 in prostate cancer progression. *Neoplasia*. 2002; 4(3):191–4. Epub 2002/05/04. <https://doi.org/10.1038/sj/neo/7900224> PMID: 11988838; PubMed Central PMCID: PMC1531692.
 18. Jin H, Varner J. Integrins: roles in cancer development and as treatment targets. *Br J Cancer*. 2004; 90(3):561–5. Epub 2004/02/05. <https://doi.org/10.1038/sj.bjc.6601576> PMID: 14760364; PubMed Central PMCID: PMC2410157.
 19. Mulgrew K, Kinneer K, Yao XT, Ward BK, Damschroder MM, Walsh B, et al. Direct targeting of α v β 3 integrin on tumor cells with a monoclonal antibody, Abegrin. *Mol Cancer Ther*. 2006; 5(12):3122–9. Epub 2006/12/19. <https://doi.org/10.1158/1535-7163.MCT-06-0356> PMID: 17172415.
 20. Niu J, Li Z. The roles of integrin α v β 6 in cancer. *Cancer Lett*. 2017; 403:128–37. Epub 2017/06/22. <https://doi.org/10.1016/j.canlet.2017.06.012> PMID: 28634043.
 21. Lu H, Wang T, Li J, Fedele C, Liu Q, Zhang J, et al. α v β 6 Integrin Promotes Castrate-Resistant Prostate Cancer through JNK1-Mediated Activation of Androgen Receptor. *Cancer Res*. 2016; 76(17):5163–74. Epub 2016/07/28. <https://doi.org/10.1158/0008-5472.CAN-16-0543> PMID: 27450452; PubMed Central PMCID: PMC5012867.
 22. Dutta A, Li J, Lu H, Akech J, Pratap J, Wang T, et al. Integrin α v β 6 promotes an osteolytic program in cancer cells by upregulating MMP2. *Cancer Res*. 2014; 74(5):1598–608. Epub 2014/01/05. <https://doi.org/10.1158/0008-5472.CAN-13-1796> PMID: 24385215; PubMed Central PMCID: PMC3967411.
 23. Vlachostergios PJ, Puca L, Beltran H. Emerging Variants of Castration-Resistant Prostate Cancer. *Curr Oncol Rep*. 2017; 19(5):32. Epub 2017/04/01. <https://doi.org/10.1007/s11912-017-0593-6> PMID: 28361223; PubMed Central PMCID: PMC5479409.
 24. Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, et al. The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. *Clin Cancer Res*. 2019; 25(23):6916–24. Epub 2019/08/01. <https://doi.org/10.1158/1078-0432.CCR-19-1423> PMID: 31363002; PubMed Central PMCID: PMC6891154.
 25. Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, et al. Aggressive Variants of Castration Resistant Prostate Cancer. *Clin Cancer Res*. 2014; 20(11):2846–50. <https://doi.org/10.1158/1078-0432.CCR-13-3309> PMID: 24727321; PubMed Central PMCID: PMC4040316.
 26. Beltran H, Tagawa ST, Park K, MacDonald T, Milowsky MI, Mosquera JM, et al. Challenges in recognizing treatment-related neuroendocrine prostate cancer. *J Clin Oncol*. 2012; 30(36):e386–9. Epub 2012/11/22. <https://doi.org/10.1200/JCO.2011.41.5166> PMID: 23169519.
 27. Parimi V, Goyal R, Poropatich K, Yang XJ. Neuroendocrine differentiation of prostate cancer: a review. *Am J Clin Exp Urol*. 2014; 2(4):273–85. PMID: 25606573; PubMed Central PMCID: 4297323.

28. Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. *Nat Med*. 2016; 22(3):298–305. Epub 2016/02/09. <https://doi.org/10.1038/nm.4045> Epub 2016 Feb 8. PMID: 26855148; PubMed Central PMCID: PMC4777652.
29. Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, et al. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. *J Clin Oncol*. 2018; 36(24):2492–503. Epub 2018/07/10. <https://doi.org/10.1200/JCO.2017.77.6880> PMID: 29985747; PubMed Central PMCID: PMC6366813.
30. Palmgren JS, Karavadia SS, Wakefield MR. Unusual and underappreciated: small cell carcinoma of the prostate. *Semin Oncol*. 2007; 34(1):22–9. Epub 2007/02/03. S0093-7754(06)00418-0 [pii] <https://doi.org/10.1053/j.seminoncol.2006.10.026> PMID: 17270662.
31. Labrecque MP, Coleman IM, Brown LG, True LD, Kollath L, Lakely B, et al. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. *J Clin Invest*. 2019; 129(10):4492–505. Epub 2019/07/31. <https://doi.org/10.1172/JCI128212> PMID: 31361600; PubMed Central PMCID: PMC6763249.
32. Nguyen HM, Vessella RL, Morrissey C, Brown LG, Coleman IM, Higano CS, et al. LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics. *Prostate*. 2017; 77(6):654–71. Epub 2017/02/06. <https://doi.org/10.1002/pros.23313> PMID: 28156002; PubMed Central PMCID: PMC5354949.
33. Krishn SR, Singh A, Bowler N, Duffy AN, Friedman A, Fedele C, et al. Prostate cancer sheds the α V β 3 integrin in vivo through exosomes. *Matrix Biol*. 2019; 77:41–57. <https://doi.org/10.1016/j.matbio.2018.08.004> PMID: 30098419; PubMed Central PMCID: 6541230.
34. Weinreb PH, Simon KJ, Rayhorn P, Yang WJ, Leone DR, Dolinski BM, et al. Function-blocking integrin α v β 6 monoclonal antibodies: distinct ligand-mimetic and nonligand-mimetic classes. *J Biol Chem*. 2004; 279(17):17875–87. Epub 2004/02/13. <https://doi.org/10.1074/jbc.M312103200> PMID: 14960589.
35. Garlick DS, Li J, Sansoucy B, Wang T, Griffith L, FitzGerald T, et al. α V β 6 integrin expression is induced in the POET and Ptenpc^{-/-} mouse models of prostatic inflammation and prostatic adenocarcinoma. *Am J Transl Res*. 2012; 4(2):165–74. PMID: 22611469; PubMed Central PMCID: 3353537.
36. Sun H, Wang Y, Chinnam M, Zhang X, Hayward SW, Foster BA, et al. E2f binding-deficient Rb1 protein suppresses prostate tumor progression in vivo. *Proc Natl Acad Sci U S A*. 2011; 108(2):704–9. Epub 2010/12/29. <https://doi.org/10.1073/pnas.1015027108> PMID: 21187395; PubMed Central PMCID: PMC3021049.
37. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. *Cancer Cell*. 2003; 4(3):209–21. Epub 2003/10/03. [https://doi.org/10.1016/s1535-6108\(03\)00215-0](https://doi.org/10.1016/s1535-6108(03)00215-0) PMID: 14522255.
38. Goel HL, Sayeed A, Breen M, Zarif MJ, Garlick DS, Leav I, et al. β 1 integrins mediate resistance to ionizing radiation in vivo by inhibiting c-Jun amino terminal kinase 1. *J Cell Physiol*. 2013; 228:1601–9. Epub 2013/01/30. <https://doi.org/10.1002/jcp.24323> PMID: 23359252.
39. Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. *Science*. 2017; 355(6320):78–83. <https://doi.org/10.1126/science.aah4199> PMID: 28059767; PubMed Central PMCID: PMC5367887.
40. Hsu EC, Rice MA, Bermudez A, Marques FJG, Aslan M, Liu S, et al. Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1. *Proc Natl Acad Sci U S A*. 2020; 117(4):2032–42. Epub 2020/01/15. <https://doi.org/10.1073/pnas.1905384117> PMID: 31932422; PubMed Central PMCID: PMC6994991.
41. Zhang W, Liu B, Wu W, Li L, Broom BM, Basourakos SP, et al. Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. *Clin Cancer Res*. 2018; 24(3):696–707. Epub 2017/11/16. <https://doi.org/10.1158/1078-0432.CCR-17-1872> PMID: 29138344; PubMed Central PMCID: PMC5823274.
42. Bhagirath D, Yang TL, Tabatabai ZL, Majid S, Dahiya R, Tanaka Y, et al. BRN4 Is a Novel Driver of Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer and Is Selectively Released in Extracellular Vesicles with BRN2. *Clin Cancer Res*. 2019; 25(21):6532–45. Epub 2019/08/03. <https://doi.org/10.1158/1078-0432.CCR-19-0498> Epub 2019 Aug 1. PMID: 31371344; PubMed Central PMCID: PMC6825556.
43. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, et al. Prostate cancer in a transgenic mouse. *Proc Natl Acad Sci U S A*. 1995; 92(8):3439–43. Epub 1995/04/11. <https://doi.org/10.1073/pnas.92.8.3439> PMID: 7724580; PubMed Central PMCID: PMC42182.

44. Gelman IH. How the TRAMP Model Revolutionized the Study of Prostate Cancer Progression. *Cancer Res.* 2016; 76(21):6137–9. Epub 2016/11/03. <https://doi.org/10.1158/0008-5472.CAN-16-2636> PMID: 27803100.
45. Dyson NJ. RB1: a prototype tumor suppressor and an enigma. *Genes Dev.* 2016; 30(13):1492–502. Epub 2016/07/13. <https://doi.org/10.1101/gad.282145.116> PMID: 27401552; PubMed Central PMCID: PMC4949322.
46. van den Heuvel S, Dyson NJ. Conserved functions of the pRB and E2F families. *Nat Rev Mol Cell Biol.* 2008; 9(9):713–24. Epub 2008/08/23. <https://doi.org/10.1038/nrm2469> PMID: 18719710.
47. Knudsen ES, Knudsen KE. Tailoring to RB: tumour suppressor status and therapeutic response. *Nat Rev Cancer.* 2008; 8(9):714–24. <https://doi.org/10.1038/nrc2401> PMID: 19143056; PubMed Central PMCID: PMC2914856.
48. Engel B, Cress W, Santiago-Cardona P. The retinoblastoma protein: a master tumor suppressor acts as a link between cell cycle and cell adhesion. *Cell Health Cytoskelet.* 2015; 7:1–10. <https://doi.org/10.2147/CHC.S28079> PMID: 28090172; PubMed Central PMCID: PMC5228373.
49. Sosa-García B, Gunduz V, Vázquez-Rivera V, Cress WD, Wright G, Bian H, et al. A Role for the Retinoblastoma Protein As a Regulator of Mouse Osteoblast Cell Adhesion: Implications for Osteogenesis and Osteosarcoma Formation. *PLoS One.* 2010; 5(11). <https://doi.org/10.1371/journal.pone.0013954> PMID: 21085651; PubMed Central PMCID: PMC2978706.
50. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. *Cancer Cell.* 2010; 18(1):11–22. Epub 2010/06/29. <https://doi.org/10.1016/j.ccr.2010.05.026> PMID: 20579941; PubMed Central PMCID: PMC3198787.
51. McNair C, Xu K, Mandigo AC, Benelli M, Leiby B, Rodrigues D, et al. Differential impact of RB status on E2F1 reprogramming in human cancer. *J Clin Invest.* 2018; 128(1):341–58. Epub 2017/12/05. <https://doi.org/10.1172/JCI93566> PMID: 29202480; PubMed Central PMCID: PMC5749518.
52. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. *J Clin Invest.* 1995; 96(4):1815–22. Epub 1995/10/01. <https://doi.org/10.1172/JCI118227> PMID: 7560073; PubMed Central PMCID: PMC185818.
53. Rader C, Popkov M, Neves JA, Barbas CF 3rd. Integrin alpha(v)beta3 targeted therapy for Kaposi's sarcoma with an in vitro evolved antibody. *Faseb j.* 2002; 16(14):2000–2. Epub 2002/10/25. <https://doi.org/10.1096/fj.02-0281fje> PMID: 12397091.
54. McCabe NP, De S, Vasanji A, Brainard J, Byzova TV. Prostate cancer specific integrin alphavbeta3 modulates bone metastatic growth and tissue remodeling. *Oncogene.* 2007; 26(42):6238–43. Epub 2007/03/21. <https://doi.org/10.1038/sj.onc.1210429> Epub 2007 Mar 19. PMID: 17369840; PubMed Central PMCID: PMC2753215.
55. Sloan EK, Pouliot N, Stanley KL, Chia J, Moseley JM, Hards DK, et al. Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. *Breast Cancer Res.* 2006; 8(2):R20. Epub 2006/04/13. <https://doi.org/10.1186/bcr1398> PMID: 16608535; PubMed Central PMCID: PMC1557720.
56. Zhao Y, Bachelier R, Treilleux I, Pujuguet P, Peyruchaud O, Baron R, et al. Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. *Cancer Res.* 2007; 67(12):5821–30. Epub 2007/06/19. <https://doi.org/10.1158/0008-5472.CAN-06-4499> PMID: 17575150.
57. Knowles LM, Gurski LA, Engel C, Gnarr JR, Maranchie JK, Pilch J. Integrin alphavbeta3 and fibronectin upregulate Slug in cancer cells to promote clot invasion and metastasis. *Cancer Res.* 2013; 73(20):6175–84. Epub 2013/08/24. <https://doi.org/10.1158/0008-5472.CAN-13-0602> PMID: 23966293; PubMed Central PMCID: PMC3837455.
58. Pecheur I, Peyruchaud O, Serre CM, Guglielmi J, Voland C, Bourre F, et al. Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone. *Faseb j.* 2002; 16(10):1266–8. Epub 2002/08/03. <https://doi.org/10.1096/fj.01-0911fje> PMID: 12153995.
59. Zheng DQ, Woodard AS, Tallini G, Languino LR. Substrate specificity of alpha(v)beta(3) integrin-mediated cell migration and phosphatidylinositol 3-kinase/AKT pathway activation. *J Biol Chem.* 2000; 275(32):24565–74. Epub 2000/06/03. <https://doi.org/10.1074/jbc.M002646200> PMID: 10835423.
60. Dardenne E, Beltran H, Benelli M, Gayvert K, Berger A, Puca L, et al. N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. *Cancer Cell.* 2016; 30(4):563–77. Epub 2016/10/12. <https://doi.org/10.1016/j.ccell.2016.09.005> PMID: 27728805; PubMed Central PMCID: PMC5540451.
61. Chesler L, Schlieve C, Goldenberg DD, Kenney A, Kim G, McMillan A, et al. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. *Cancer Res.* 2006; 66(16):8139–46. Epub 2006/08/17. <https://doi.org/10.1158/0008-5472.CAN-05-2769> PMID: 16912192; PubMed Central PMCID: PMC2924674.

62. Lee JK, Phillips JW, Smith BA, Park JW, Stoyanova T, McCaffrey EF, et al. N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. *Cancer Cell*. 2016; 29(4):536–47. Epub 2016/04/07. <https://doi.org/10.1016/j.ccell.2016.03.001> PMID: 27050099; PubMed Central PMCID: PMC4829466.
63. de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. *N Engl J Med*. 2020; 382(22):2091–102. Epub 2020/04/29. <https://doi.org/10.1056/NEJMoa1911440> PMID: 32343890.
64. Lu H, Bowler N, Harshyne LA, Craig Hooper D, Krishn SR, Kurtoglu S, et al. Exosomal $\alpha v\beta 6$ integrin is required for monocyte M2 polarization in prostate cancer. *Matrix Biol*. 2018; 70:20–35. Epub 2018/03/14. <https://doi.org/10.1016/j.matbio.2018.03.009> PMID: 29530483; PubMed Central PMCID: PMC6081240.
65. Krishn SR, Salem I, Quaglia F, Naranjo NM, Agarwal E, Liu Q, et al. The $\alpha v\beta 6$ integrin in cancer cell-derived small extracellular vesicles enhances angiogenesis. *J Extracell Vesicles*. 2020; 9(1):1763594. Epub 2020/07/01. <https://doi.org/10.1080/20013078.2020.1763594> PMID: 32595914; PubMed Central PMCID: PMC7301698.